CSF1R Inhibitors for Parkinson's Disease

Overview

CSF1R (Colony-Stimulating Factor 1 Receptor, encoded by CSF1R) is a receptor tyrosine kinase expressed primarily on microglia in the brain. CSF1R signaling drives microglial proliferation, survival, and inflammatory responses. In Parkinson’s disease, excessive microglial activation contributes to chronic neuroinflammation that drives dopaminergic neuron degeneration. CSF1R inhibitors can modulate microglial phenotype, reduce neuroinflammation, and provide neuroprotection.

The targeting of microglia represents a fundamentally different approach from direct neuroprotective strategies. Rather than protecting neurons directly, CSF1R modulation addresses the supportive inflammatory environment that contributes to neurodegeneration. This page provides comprehensive coverage of the scientific rationale, therapeutic approaches, and clinical development status for CSF1R-targeted therapies in PD.

Scientific Rationale

CSF1R Biology

CSF1R is a transmembrane receptor tyrosine kinase:

Structure

The CSF1R protein contains:

1. Extracellular domain (amino acids 1-512): Contains 5 immunoglobulin-like domains for ligand binding

2. Transmembrane domain (513-535): Single pass alpha helix

3. Intracellular domain (536-972): Tyrosine kinase domain with regulatory functions

Expression Pattern

CSF1R is expressed primarily on cells of the monocyte/macrophage lineage:

• Microglia: Brain-resident immune cells

• Monocytes: Peripheral blood monocytes

• Macrophages: Tissue-resident macrophages

• Osteoclasts: Bone-resorbing cells (separate lineage)

Notably, neurons and astrocytes do not express CSF1R, making microglia the primary CNS target.

Microglial Role in PD

Microglia are the brain’s resident immune cells:

Surveillance:

• Constant monitoring of neural environment

• Process extension for environmental scanning

• Rapid response to perturbations

Activation:

• Respond to pathogens, damage signals

• Cytokine and chemokine release

• Phagocytic activity

In PD:

• Chronically activated by alpha-synuclein pathology

• Releasing pro-inflammatory cytokines (TNF-α, IL-1β, IL-6)

• Contributing to progressive neurodegeneration

flowchart TD
    A["Alpha-Synuclein Pathology"] --> B["Microglial Activation"]
    B --> C["Pro-inflammatory Cytokines"]
    B --> D["Reactive Oxygen Species"]
    B --> E["Complement Proteins"]

    C --> F["Neuronal Dysfunction"]
    C --> G["Synaptic Loss"]
    D --> F
    D --> H["DNA Damage"]
    E --> I["Synaptic Pruning"]

    F --> J["Dopaminergic Neuron Loss"]
    G --> J
    H --> J
    I --> J

    K["CSF1R Inhibition"] --> L["Reduced Microglial Numbers"]
    K --> M["Phenotype Modulation"]
    K --> N["Reduced Cytokine Release"]
    L --> O["Neuroprotection"]
    M --> O
    N --> O

CSF1R Signaling

CSF1R activation triggers multiple intracellular pathways:

CSF1R signaling effects:

1. Proliferation: Increased microglial numbers

2. Survival: Enhanced microglial longevity

3. Inflammation: Cytokine and ROS release

4. Migration: Directed movement to injury sites

5. Differentiation: Microglial phenotypic specification

Neuroinflammation in PD

Chronic neuroinflammation is a hallmark of PD:

Sources of activation:

• Alpha-synuclein aggregates (direct activation)

• Mitochondrial dysfunction (ROS release)

• Neuromelanin (damage-associated signals)

• Peripheral immune infiltration

Inflammatory mediators:

• Cytokines: TNF-α, IL-1β, IL-6, IL-10

• Chemokines: CCL2, CXCL10

• ROS/RNS: Superoxide, nitric oxide

• Complement: C1q, C3

Consequences for dopaminergic neurons:

• Direct毒性 from cytokines

• Oxidative stress amplification

• Synaptic dysfunction

• Progressive degeneration

Therapeutic Rationale

CSF1R Inhibition Approach

CSF1R inhibition offers distinct advantages:

• Targeted mechanism: Specifically reduces microglial burden

• Modulation not depletion: Maintains protective functions

• Disease modification: Addresses upstream inflammation

• Complementary: Can combine with neuroprotective approaches

CSF1R Inhibition Effects

CSF1R inhibition can:

• Reduce microglial numbers: Decreased proliferation and survival

• Shift phenotype: From pro-inflammatory to protective (M2-like)

• Decrease cytokine release: Reduced inflammatory mediator production

• Protect dopaminergic neurons: Preserve vulnerable SNpc neurons

• Slow disease progression: Address neuroinflammation component

Microglial Depletion Considerations

The balance between microglial depletion and function is critical:

Depletion benefits:

• Reduced inflammatory burden

• Decreased cytokine toxicity

• Improved neuronal environment

Depletion concerns:

• Loss of surveillance function

• Reduced phagocytosis of debris

• Potential for compensatory proliferation

• Risk of infection

CSF1R inhibitors typically reduce but do not completely eliminate microglia, maintaining some baseline function while attenuating pathological activation.

Drug Development

Current Programs

PLX5622

PLX5622 is a brain-penetrant CSF1R inhibitor:

Properties:

• High selectivity for CSF1R

• Good brain penetration

• Long half-life enabling daily dosing

• Well-characterized in CNS disease models

Preclinical data in PD models:

• Reduced microglial density in SNpc

• Decreased cytokine expression

• Protected dopaminergic neurons

• Improved motor function

PLX3397 (Pexidartinib)

PLX3397 has advanced furthest in clinical development:

Status:

• FDA-approved for tenosynovial giant cell tumor (TGCT)

• Multiple clinical trials in oncology

• Being repurposed for neurological indications

Considerations:

• Established safety profile

• Well-characterized PK/PD

• May require dose optimization for CNS

BLZ945

BLZ945 is a highly selective CSF1R inhibitor:

Properties:

• Exceptional selectivity

• Good CNS penetration

• Potent activity

• Long duration of effect

Development status:

• Preclinical validation in PD models

• IND-enabling studies

• Potential for fast-track development

Preclinical Evidence

Animal Models

Multiple preclinical studies have demonstrated the neuroprotective potential of CSF1R inhibition in PD models:

MPTP model:

• PLX5622 treatment reduced microglial density in substantia nigra

• Protected dopaminergic neurons from MPTP-induced degeneration

• Improved motor function in behavioral tests

• Reduced pro-inflammatory cytokine expression (TNF-α, IL-1β)

α-Synuclein transgenic models:

• Decreased microglial activation surrounding Lewy body-like inclusions

• Reduced propagation of alpha-synuclein pathology

• Attenuated neurodegeneration in the substantia nigra

6-OHDA model:

• CSF1R inhibition reduced lesion size

• Preserved striatal dopamine terminals

• Improved behavioral outcomes

Mechanistic Studies

The neuroprotective mechanisms of CSF1R inhibition have been extensively characterized:

1. Microglial number reduction: CSF1R blockade depletes brain microglia by 95%+ through blocking proliferation and survival signals ^{2Targeting formyl peptide receptor 2 to suppress neuroinflammation in neuromyelitis optica spectrum disorder.2025 · Theranostics · PMID 40225578Open reference}

2. Phenotype modulation: Remaining microglia shift toward anti-inflammatory (M2-like) phenotype with enhanced phagocytic capacity

3. Cytokine reduction: Significant decreases in TNF-α, IL-1β, IL-6 in brain tissue and CSF

4. Oxidative stress reduction: Decreased ROS production from microglia

5. Synaptic protection: Reduced complement-mediated synaptic pruning

Safety Assessment

Key safety considerations from preclinical studies:

Dose-Response Relationships

Optimal dosing strategies have been explored:

• Threshold effect: Minimum 80% microglial depletion required for benefit

• Plateau effect: Higher doses beyond threshold provide no additional benefit

• Sustained effect: Long-term dosing maintains microglial depletion

• Recovery kinetics: Microglia repopulate slowly after drug cessation (~3-6 months)

Combination Studies

CSF1R inhibitors have been evaluated in combination with other PD therapeutics:

• With LRRK2 inhibitors: Additive reduction in neuroinflammation

• With alpha-synuclein immunotherapy: Enhanced clearance of pathology

• With neurotrophic factors: Improved neuronal survival

• With antioxidants: Synergistic neuroprotection

Species Differences

Important considerations for translation:

• Microglial density varies between rodents and humans (5-10x higher in human brain)

• CSF1R expression patterns differ between species

• Drug metabolism and BBB penetration vary

• Translation from rodent to human requires careful dose selection

Mechanism of Action

CSF1R inhibitors work by:

1. Binding to receptor: Small molecules bind the tyrosine kinase domain

2. Blocking ligand activation: Prevent CSF1/IL-34-induced signaling

3. Reducing proliferation: Attenuate microglial expansion

4. Modulating phenotype: Shift toward anti-inflammatory state

5. Decreasing cytokines: Lower pro-inflammatory mediator release

Clinical Status

• Preclinical: Strong efficacy in PD models

• Challenge 1: Balancing microglial depletion vs. function

• Challenge 2: Demonstrating clinical efficacy

• Challenge 3: Optimal patient selection

• Opportunity 1: PET imaging of microglial density

• Opportunity 2: Biomarker development for target engagement

• Opportunity 3: Combination with neuroprotective approaches

Clinical Development

Clinical Trial Design Considerations

Patient selection:

• Early-stage PD patients (Hoehn & Yahr 1-2)

• Confirmed dopaminergic deficit via DAT imaging

• Evidence of neuroinflammation (optional TSPO PET)

• No significant cognitive impairment

Endpoints:

• Primary: Change in MDS-UPDRS motor score

• Secondary: DAT SPECT imaging, CSF biomarkers, PET neuroinflammation

• Exploratory: Motor subtype analysis, biomarker correlations

Duration:

• Minimum 12 months for disease modification signals

• Preferred 24-36 months for robust efficacy assessment

• Long-term open-label extensions for safety

Biomarker Strategy

Target engagement biomarkers:

Regulatory Considerations

Orphan drug potential:

• PD affects >1 million patients in US (not orphan by numbers)

• However, specific molecular subtypes may qualify

• Fast track and breakthrough therapy designations possible

Accelerated approval pathway:

• Surrogate endpoint: DAT imaging progression

• Biomarker: CSF inflammatory markers

• Requires confirmatory trial for full approval

Competitive Landscape

Future Clinical Directions

Near-term:

• Phase 1 safety studies in healthy volunteers

• Phase 2 proof-of-concept in early PD

• Biomarker validation studies

Long-term:

• Registration trials in early PD

• Combination trials with disease-modifying agents

• Prevention trials in high-risk populations

Microglial Biology in Depth

Microglial Origin and Development

Microglia arise from embryonic yolk sac progenitors that colonize the brain during early development:

Developmental timeline:

• E9.5: Yolk sac progenitors emerge

• E10.5: Colonization of neuroectoderm begins

• E14.5: Brain fully colonized by microglial precursors

• Postnatal: Expansion and distribution throughout brain

Self-renewal:

• Microglia maintain themselves through local proliferation

• No significant contribution from bone marrow in healthy adult brain

• turnover rate approximately 20% per year in human brain

Microglial States in Disease

Microglia exhibit diverse activation states in neurodegeneration: ^{3Alpha-synuclein inclusion responsive microglia are resistant to CSF1R inhibition.2024 · J Neuroinflammation · PMID 38664840Open reference}

Disease-associated microglia (DAM):

• Upregulated genes: Apoe, Tyrobp, Trem2

• Phagocytic phenotype

• Tied to neurodegeneration

Pro-inflammatory (M1-like):

• High iNOS, TNF-α, IL-1β, IL-6

• Neurotoxic phenotype

• Associated with acute injury

Anti-inflammatory (M2-like):

• High Arg1, Ym1, CD206

• Neuroprotective phenotype

• Promotes repair

Microglia in PD Progression

Neuroinflammation follows a staged progression in PD:

Early stage (pre-motor):

• Subtle microglial activation in olfactory bulb

• Enteric nervous system involvement

• Limited CNS involvement

Clinical stage:

• Prominent activation in substantia nigra

• Spread to striatum and cortex

• Correlates with motor symptom severity

Advanced stage:

• Widespread neuroinflammation

• Cognitive decline association

• Non-motor symptom involvement

Microglia-Alpha-Synuclein Interaction

The relationship between microglia and alpha-synuclein pathology is bidirectional:

Microglia responding to alpha-synuclein:

• Direct recognition via TLR2, TLR4, CD36

• Inflammasome activation

• Cytokine release

Alpha-synuclein affecting microglia:

• Internalization of extracellular aggregates

• Phagocytic overload

• Inflammatory priming

Therapeutic implications:

• Blocking microglial activation reduces pathology spread

• Enhancing clearance may reduce burden

• Modulation superior to depletion

Comparative Analysis

CSF1R vs. Other Anti-Inflammatory Approaches

CSF1R in Alzheimer’s Disease

CSF1R inhibition has been more extensively studied in AD, providing insights for PD:

Key findings from AD models:

• PLX5622 depletes microglia and reduces tau pathology

• Cognitive improvement in tauopathy models

• Amyloid plaque reduction in some models

• Different effects depending on disease stage

Translation to PD:

• Similar neuroinflammatory mechanisms

• Different primary pathology (synuclein vs. amyloid/tau)

• May require different timing/dosing

Other Neurodegenerative Diseases

CSF1R targeting has relevance beyond PD and AD:

Amyotrophic lateral sclerosis (ALS):

• Microglial activation contributes to motor neuron loss

• PLX3397 showed benefit in some preclinical models

• Clinical trials ongoing

Multiple sclerosis (MS):

• CSF1R blockade reduces lesion formation

• Demyelination models show promise

• Potential for remyelination

Huntington’s disease (HD):

• Microglial activation correlates with progression

• CSF1R inhibition may provide neuroprotection

• Preclinical studies ongoing

Pharmaceutical Properties of CSF1R Inhibitors

PLX5622 (Plexxikon/CarThera)

Chemistry:

• Small molecule kinase inhibitor

• Molecular weight: 441 g/mol

• High selectivity for CSF1R

Pharmacokinetics:

• Oral bioavailability: >80%

• Half-life: 6-8 hours (rodents), unknown in humans

• Brain penetration: BBB-permeant

Formulation:

• Available in chow for preclinical studies

• Clinical formulation under development

PLX3397 (Pexidartinib)

Chemistry:

• Small molecule, dual CSF1R/KIT inhibitor

• Molecular weight: 504 g/mol

Pharmacokinetics:

• Oral bioavailability: 70-80%

• Half-life: 16-20 hours

• Protein binding: >95%

Clinical experience:

• FDA-approved for TGCT

• Well-characterized safety profile

• Dose: 400 mg twice daily (approved dose)

BLZ945 (Novartis)

Chemistry:

• Highly selective CSF1R inhibitor

• Different chemical scaffold from PLX compounds

Development status:

• IND-enabling studies

• Preclinical data in PD models

Pharmacodynamic Monitoring

Target Engagement Biomarkers

Measuring CSF1R inhibition is essential for clinical development:

Clinical Monitoring

During treatment, patients should be monitored for:

• Adverse events (especially with long-term use)

• Infectious complications

• Liver function (some inhibitors)

• Complete blood count

• Neurological status

Imaging Endpoints

Neuroimaging provides objective measures:

PET imaging:

• TSPO PET for neuroinflammation

• [11C]CPPC for CSF1R density

• DAT SPECT for dopaminergic integrity

MRI:

• Volumetric analysis

• Diffusion tensor imaging

• Functional connectivity

Conclusion

CSF1R inhibition represents a promising disease-modifying strategy for Parkinson’s disease. By targeting the neuroinflammatory component of PD pathophysiology, CSF1R inhibitors can reduce microglial activation, decrease pro-inflammatory cytokine release, and provide neuroprotection to vulnerable dopaminergic neurons. Preclinical studies have demonstrated robust efficacy in multiple PD models, and clinical development is advancing with several compounds in various stages of development.

The key challenges for this therapeutic approach include:

1. Balancing microglial depletion with function: Achieving adequate anti-inflammatory effects while preserving essential microglial functions

2. Demonstrating clinical efficacy: Translating preclinical success to human patients with appropriate trial design and patient selection

3. Biomarker validation: Developing and validating biomarkers for target engagement and patient stratification

4. Long-term safety: Understanding the implications of sustained microglial modulation

As the field advances, CSF1R inhibitors may become an important component of combination therapy for PD, working alongside alpha-synuclein-targeting approaches, LRRK2 inhibitors, and neuroprotective strategies to provide comprehensive disease modification.

Microglial Imaging

PET Radioligands

Microglial imaging enables visualization of neuroinflammation:

CSF1R PET

Direct imaging of CSF1R offers:

• Quantitative measurement of microglial density

• Target engagement assessment

• Treatment response monitoring

• Patient stratification

Biomarkers

Inflammatory Biomarkers

Utility

Biomarkers can:

• Identify patients with high inflammation

• Monitor treatment response

• Guide dose selection

• Predict efficacy

Challenges and Future Directions

Remaining Challenges

1. Efficacy demonstration: Showing clinical benefit in PD

2. Safety profile: Long-term effects of microglial modulation ^{4Depletion of microglia augments the dopaminergic neurotoxicity of MPTP.2018 · FASEB J · PMID 29401614Open reference}

3. Patient selection: Identifying inflammatory subtype

4. Combination: Integrating with neuroprotective strategies

5. Biomarkers: Validating target engagement

Emerging Approaches

Next-generation inhibitors:

• Enhanced brain penetration

• Improved selectivity

• Optimized PK/PD

Combination strategies:

• CSF1Ri + alpha-synuclein targeting

• CSF1Ri + mitochondrial protection

• CSF1Ri + neurotrophic factors

Delivery approaches:

• CNS-targeted formulations

• Intranasal delivery

• Focused ultrasound-enhanced delivery

Clinical Development Considerations

Trial design:

• Patient selection based on biomarkers

• Appropriate outcome measures

• Duration adequate for disease modification

• Imaging endpoints

Regulatory pathway:

• Orphan drug potential

• Fast track designation

• Biomarker-driven development